长期使用艾曲泊帕治疗骨髓衰竭会耗竭铁
该回顾性研究比较了NIH治疗的521例骨髓衰竭患者(315例接受艾曲泊帕,206例接受免疫抑制治疗),发现艾曲泊帕暴露时长与铁蛋白降低相关(p=4×10⁻¹⁴),铁清除半衰期为15.3个月,快于历史应答者的47.5个月(p=8×10⁻¹⁰),长期使用可致缺铁性贫血,补充铁可纠正。
要点
- 艾曲泊帕暴露时长与铁蛋白降低相关,与应答、最大剂量或初始铁过载程度无关。
- 铁清除半衰期为15.3个月,历史应答者为47.5个月(p=8×10⁻¹⁰)。
- 长期使用可耗竭铁导致缺铁性贫血,模拟复发,补充铁可纠正。
核心结论
- 艾曲泊帕能有效螯合全身铁,与临床可用的螯合剂相当。
- 长期使用可耗竭铁并最终导致缺铁性贫血,模拟复发,补充铁可纠正。
研究设计与样本
- 回顾性研究,纳入NIH治疗的521例骨髓衰竭患者,其中艾曲泊帕组315例,无艾曲泊帕的历史对照206例,涉及11项研究,随访时间分别为3.6年与8.5年。
主要发现
- 艾曲泊帕暴露时长与铁蛋白降低相关(p=4×10⁻¹⁴),与应答、最大剂量或初始铁过载程度无关。
- 铁清除半衰期为15.3个月,历史应答者为47.5个月(p=8×10⁻¹⁰)。
- 铁耗竭风险取决于基线铁蛋白和治疗时长。
- 基线铁蛋白与骨髓衰竭对艾曲泊帕的应答或复发风险无关,铁清除时机与疾病应答无关。
关键数值与推荐
- 艾曲泊帕组315例,无艾曲泊帕组206例,随访时间分别为3.6年与8.5年。
- 铁蛋白降低与艾曲泊帕暴露时长相关,p=4×10⁻¹⁴。
- 铁清除半衰期艾曲泊帕组15.3个月 vs 历史应答者47.5个月,p=8×10⁻¹⁰。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eltrombopag (EPAG) has been approved for the treatment of aplastic anemia and for immune thrombocytopenia, and a subset of patients require long-term therapy. Due to polyvalent cation chelation, prolonged therapy leads to previously underappreciated iron depletion. We conducted a retrospective review of patients treated at the NIH for aplastic anemia, myelodysplastic syndrome, and unilineage cytopenias, comparing those treated with EPAG to a historical cohort treated with immunosuppression without EPAG. We examined iron parameters, duration of therapy, response assessment, relapse rates, and common demographic parameters. We included 521 subjects treated with (n = 315) or without EPAG (n = 206) across 11 studies with multiyear follow-up (3.6 vs. 8.5 years, respectively). Duration of EPAG exposure correlated with ferritin reduction (p = 4 × 10-14 ) regardless of response, maximum dose, or degree of initial iron overload. Clearance followed first-order kinetics with faster clearance (half-life 15.3 months) compared with historical responders (47.5 months, p = 8 × 10-10 ). Risk of iron depletion was dependent upon baseline ferritin and duration of therapy. Baseline ferritin did not correlate with response of marrow failure to EPAG or to relapse risk, and timing of iron clearance did not correlate with disease response. In conclusion, EPAG efficiently chelates total body iron comparable to clinically available chelators. Prolonged use can deplete iron and ultimately lead to iron-deficiency anemia mimicking relapse, responsive to iron supplementation.
引用
- Young DJ, Fan X, Groarke EM, et al. Long-term eltrombopag for bone marrow failure depletes iron. Am J Hematol. 2022. PMID: 35312200. doi:10.1002/ajh.26543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。